Amgen Stock Setup On FDA Approval for Multiple Myeloma

Amgen stock looks like a good setup as the Twiggs Money Flow breaks into positive territory.

Summary

  • The FDA has approved Amgen's supplemental Biologics License Application to expand the label of its key drug Xgeva.
  • Amgen stock is in a continuation pattern and the Twiggs Money Flow has just gone positive.
  • Amgen has nearly $39 billion in cash overseas that could be put to use in the United States.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Regeneron Pharmaceuticals Stock Growth Play On Rising Large Players Volume

    Regeneron Pharmaceuticals stock has rising large players volume and Twiggs Money Flow, while the stock is consolidating. This positive divergence is one of my favorite bull signals.

    Summary

  • Regeneron Pharmaceuticals stock has rising large players volume while the stock is chopping out sideways in a consolidation pattern.
  • In the last two weeks, Regeneron has received two FDA approvals of Kevzara and Dupixent.
  • The company has excellent revenue growth and is a growth play.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    BioMarin Pharmaceutical Stock Doing Double Bottom Consolidation

    BioMarin Pharmaceutical stock is putting in a basing pattern after a big sell-off. The company has recently put in some impressive growth numbers.

    BioMarin Pharmaceutical stock has formed a basing or consolidation pattern on the chart with a good looking double bottom put in.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Celgene Stock Now Oversold After Miss and Stopped REVOLVE Trial

    Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.

    Celgene stock looks like a good oversold setup. The stock plunged -35% when the news broke that Celgene stopped its phase 3 trial of REVOLVE and lowered guidance for 2020. I think the sell-off that followed is now over.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Top News Stories November 14 2017

    The day's top news stories from stocks on the GuerillaStockTrading watch list.
    Continue reading “Top News Stories November 14 2017”

    Top News Stories For November 13 2017

    The day's top news stories from stocks on the GuerillaStockTrading watch list.
    Continue reading “Top News Stories For November 13 2017”

    Top Weekend News Stories November 11 – 12, 2017

    The top news stories this weekend from stocks on the GuerillaStockTrading watch list.
    Continue reading “Top Weekend News Stories November 11 – 12, 2017”

    Top Earnings Beats For the Week Ending November 10 2017

    Below are the top earnings and/or revenue beats for the week ending November 10, 2017. The table below is sorted by the biggest beats in descending order (at the top).
    Continue reading “Top Earnings Beats For the Week Ending November 10 2017”

    Intercept Pharmaceuticals Rising Large Players Volume

    Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.

    Intercept Pharmaceuticals has rising large players volume while the stock has formed a basing pattern. This is a very bullish technical setup.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Bluebird Bio Stock Strong Uptrend On Buy Ratings

    While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.

    Bluebird Bio stock is in a strong uptrend as the number of analysts with Buy ratings surge.

    BTIG upgraded Bluebird Bio stock from Neutral to Buy, and set a price target of $177. BTIG thinks that positive signals are coming from the FDA concerning bluebird bio's latest CAR-T therapy for advanced stage multiple myeloma patients. Earlier this year, bluebird bio's precursor to bb21217, named bb2121, delivered a 100% response rate among 15 multiple myeloma patients.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.